Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,085 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atherosclerosis Cardiovascular Disease Clear all
Active, not recruiting Phase 4 Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis

NCT00512720
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 90 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

NCT03590769
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Intermittent, Claudication, PAD, SFA - Superficial Femoral Artery Stenosis, Iliac Artery Disease, Vascular Calcification
Interventions
18F-FDG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

NCT01258907
View directory record Official record
Conditions
Atherosclerosis
Interventions
MLDL1278A, placebo, statin, stable dose
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
22
States / cities
Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:40 AM EDT
Active, not recruiting Phase 1 Interventional

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692
View directory record Official record
Conditions
Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases
Interventions
Tetrahydrobiopterin 10 mg/kg, Tetrahydrobiopterin 20 mg/kg, L-Ascorbate, L-Arginine
Drug
Lead sponsor
Louis Messina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Not listed Phase 1 Interventional

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

NCT00311805
View directory record Official record
Conditions
Peripheral Artery Disease, Severe Intermittent Claudication
Interventions
Autologous Stem Cells (CD34+)
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications

NCT00796822
View directory record Official record
Conditions
HIV, Cardiovascular Diseases, Atherosclerosis
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting No phase listed Observational

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

NCT06567795
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease
Interventions
Hemotag
Device
Lead sponsor
Aventusoft, LLC.
Industry
Eligibility
40 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Davenport, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 18, 2026, 5:40 AM EDT
Not listed Phase 4 Interventional

Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions

NCT00640744
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound

NCT03495453
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS, Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 2Phase 3 Interventional

TART - Troglitazone Atherosclerosis Regression Trial

NCT00116545
View directory record Official record
Conditions
Atherosclerosis, Diabetes Mellitus
Interventions
troglitazone
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
30 Years to 70 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 18, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
MEDI6012, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

RNA Cloning and Visualization in Human Atherosclerosis

NCT01928095
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting Phase 3 Interventional

The Prevent Coronary Artery Disease Trial

NCT06494501
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
30 Years to 50 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Terminated Not applicable Interventional Results available

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

NCT00106938
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions
Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical)
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional

Fisetin to Reduce Senescence and Mobility Impairment in PAD

NCT06399809
View directory record Official record
Conditions
Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases, Walking, Difficulty, Claudication
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

NCT05811364
View directory record Official record
Conditions
Aortoiliac Occlusive Disease, Peripheral Arterial Disease
Interventions
Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
26
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454
View directory record Official record
Conditions
Metabolic Disease, Obesity, Li-Fraumeni Syndrome, Cardiomyopathy, Atherosclerosis, Inflammatory Disease
Interventions
NSR IDE-MRI: Research pulse sequences
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Local Paclitaxel Delivery for SFA Disease

NCT00821028
View directory record Official record
Conditions
Atherosclerosis, Angioplasty, Peripheral Arterial Disease
Interventions
Paclitaxel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting Phase 4 Interventional

Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

NCT02842424
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ramipril
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 18, 2026, 5:40 AM EDT